Floatz logo

azd8853

Urinary Bladder Neoplasms

AstraZenecaPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Urinary Bladder Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Merck Sharp & Dohme LLC
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Eli Lilly and Company
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 2BB
Pembrolizumab
Eli Lilly and Company
Phase 2BB
Nivolumab
Ikena Oncology
Phase 2B

View all 37 →

Same molecule, other indications

azd8853 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →